The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11
HCQ was found to be consistently effective against COVID-19 when provided early in the
COVID-19 prevention and treatment: a critical analysis of chloroquine and
COVID-19 vaccines significantly reduce the chances of severe illness, hospitalization and
Several in vitro studies have proven their effectiveness on severe acute respiratory syndrome virus and currently both in vitro and in vivo studies have been conducted on 2019 novel coronavirus (covid-19)
During the first year of the COVID-19 pandemic, unauthorized drugs were widely used
This systematic review and meta-analysis aimed to examine the efficacy and safety of HCQ COVID-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
Ivermectin and hydroxychloroquine are drugs that inhibit viral replication in vitro and that have been used in several medical centers
S
After adjusting for several key confounders (see table), the use of hydroxycholoroquine + azithromycin was associated with a 66% reduction in risk of death as compared to controls; the analysis also suggested more substantial effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease (PO2/FiO2 > 300
Only alpha- and beta-coronavirus can infect humans, and both result in mild or severe respiratory infectious diseases [2,3,4]
Due to the alarmingly high basic reproduction number [], hospitalization rate [] and mortality rate [], numerous collaborative studies were
5% (2/31) (Chen Z
Hydroxychloroquine was found to reduce mortality in healthy, SARS-Cov-2 positive patients and improve clinical recovery in renal transplant recipients
2020 Nov/Dec;27 (6):e573-e583
Among the first promising repurposing agents proposed for treatment and
In these cases pharmacological prophylaxis would be a solution to reduce severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) transmission
Methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and LILACS (January 2019 to March 2021) for patients aged 18 years or older